What is Cardio Diagnostics?
Cardio Diagnostics operates at the intersection of biotechnology and artificial intelligence, focusing on the development of epigenetics-based diagnostic tools. The company is fundamentally redefining cardiovascular disease prevention by providing clinicians with actionable insights through its flagship Epi+Gen CHD test. By integrating advanced molecular diagnostics with machine learning, the firm enables a more personalized approach to patient risk assessment. This technological framework is designed to make early detection more accessible and precise, effectively establishing a new standard for cardiovascular health management in clinical settings.
How much funding has Cardio Diagnostics raised?
Cardio Diagnostics has raised a total of $11.4M across 1 funding round:
Debt
$11.4M
Debt (2023): $11.4M, investors not publicly disclosed
Key Investors in Cardio Diagnostics
Cardio Diagnostics
Undisclosed investor participating in the funding round.
What's next for Cardio Diagnostics?
With this major strategic investment, Cardio Diagnostics is poised to scale its operational capabilities and expand the clinical adoption of its diagnostic suite. The company's roadmap likely involves deepening its research into epigenetic markers and enhancing its AI-driven analytical platforms to support broader diagnostic applications. As the firm transitions into a more mature growth phase, the focus will remain on securing regulatory milestones and fostering partnerships with healthcare providers to integrate its precision medicine solutions into standard care protocols. This capital infusion provides the necessary runway to solidify its market position as a leader in the proactive cardiovascular health sector.
See full Cardio Diagnostics company page
